Manasi Manasvi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Manasi Manasvi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Abhishek Arora
Department of Surgical Gastroenterology, All India Institute of Medical Sciences, Patna, India
1 shared publication - Aparimita Das
Faculty of Allied Health Sciences, Chettinad Academy of Research and Education, Chennai 600001, India
1 shared publication - Aruni Ghose
Cardio-Oncology Service, University College London Hospitals NHS Foundation Trust, London NW1 2PG, UK
1 shared publication - Ashesh Kumar Jha
Department of General Surgery, AIIMS, Patna, Bihar, India
1 shared publication - Basant Narayan Singh
Department of Surgical Gastroenterology, All India Institute of Medical Sciences, Patna, India
1 shared publication - Deepika Gupta
Microbiology, College of Medicine and Sagore Dutta Hospital, Kolkata 700001, India
1 shared publication
Latest Publications
- Top Cited Papers
- 2 January 2026
- Published by Springer Nature in Hernia
- Vol. 30 (1) , 47
SurgiCut-AI: an AI-driven tool for predicting surgical site infections following ventral hernia repair using pre- and intra-operative parameters
Purpose Surgical Site Infection (SSI) is the common consequence of hernia surgery. This study aimed to develop an artificial intelligence (AI)-driven predictive model for SSI following open ventral hernia repair using pre- and intra-operative parameters for early detection. Methods A prospective analysis of ventral hernia patients was conducted. Demographic, pre-operative and intra-operative parameters were collected. Feature selection using Recursive Feature Elimination (RFE) identified key predictors. Five models, eXtreme Gradient Boosting (XGBoost), logistic regression, support vector machine (SVM), Adaptive Boosting and random forest (RF), were trained and validated. Results Among 253 patients, 22 were SSI-positive. RF demonstrated the highest predictive power (area under receiver operating characteristic curve = 0.82) and diagnostic odds ratio (DOR = 55). Seven key predictors were identified: defect size area, HbA1c, lymphocytes, neutrophil-to-lymphocyte ratio, blood loss (ml), platelet count and serum albumin. Decision curve analysis showed an estimated risk stratification at an 8.3% cutoff “https://surgicut-ai.netlify.app/”. Conclusion The model’s high accuracy supports its potential for clinical decision-making. External validation is required for real-world application. Integrating this AI model into bedside tools may enhance SSI prevention, especially in resource-limited settings.
- 2 January 2026
- Published by Springer Nature in Hernia
- Vol. 30 (1) , 47
Top Cited PapersSurgiCut-AI: an AI-driven tool for predicting surgical site infections following ventral hernia repair using pre- and intra-operative parameters
Purpose Surgical Site Infection (SSI) is the common consequence of hernia surgery. This study aimed to develop an artificial intelligence (AI)-driven predictive model for SSI following open ventral hernia repair using pre- and intra-operative parameters for early detection. Methods A prospective analysis of ventral hernia patients was conducted. Demographic, pre-operative and intra-operative parameters were collected. Feature selection using Recursive Feature Elimination (RFE) identified key predictors. Five models, eXtreme Gradient Boosting (XGBoost), logistic regression, support vector machine (SVM), Adaptive Boosting and random forest (RF), were trained and validated. Results Among 253 patients, 22 were SSI-positive. RF demonstrated the highest predictive power (area under receiver operating characteristic curve = 0.82) and diagnostic odds ratio (DOR = 55). Seven key predictors were identified: defect size area, HbA1c, lymphocytes, neutrophil-to-lymphocyte ratio, blood loss (ml), platelet count and serum albumin. Decision curve analysis showed an estimated risk stratification at an 8.3% cutoff “https://surgicut-ai.netlify.app/”. Conclusion The model’s high accuracy supports its potential for clinical decision-making. External validation is required for real-world application. Integrating this AI model into bedside tools may enhance SSI prevention, especially in resource-limited settings.
- Open Access
- 10 July 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (7) , 1119
COVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?
COVID-19 has been responsible for widespread morbidity and mortality worldwide. Invasive mucormycosis has death rates scaling 80%. India, one of the countries hit worst by the pandemic, is also a hotbed with the highest death rates for mucormycosis. Cancer, a ubiquitously present menace, also contributes to higher case fatality rates. All three entities studied here are individual, massive healthcare threats. The danger of one disease predisposing to the other, the poor performance status of patients with all three diseases, the impact of therapeutics for one disease on the pathology and therapy of the others all warrant physicians having a better understanding of the interplay. This is imperative so as to effectively establish control over the individual patient and population health. It is important to understand the interactions to effectively manage all three entities together to reduce overall morbidity. In this review article, we search for an inter-relationship between the COVID-19 pandemic, emerging mucormycosis, and the global giant, cancer.
- 10 July 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (7) , 1119
Open AccessCOVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?
COVID-19 has been responsible for widespread morbidity and mortality worldwide. Invasive mucormycosis has death rates scaling 80%. India, one of the countries hit worst by the pandemic, is also a hotbed with the highest death rates for mucormycosis. Cancer, a ubiquitously present menace, also contributes to higher case fatality rates. All three entities studied here are individual, massive healthcare threats. The danger of one disease predisposing to the other, the poor performance status of patients with all three diseases, the impact of therapeutics for one disease on the pathology and therapy of the others all warrant physicians having a better understanding of the interplay. This is imperative so as to effectively establish control over the individual patient and population health. It is important to understand the interactions to effectively manage all three entities together to reduce overall morbidity. In this review article, we search for an inter-relationship between the COVID-19 pandemic, emerging mucormycosis, and the global giant, cancer.